BioCryst Pharmaceuticals,Inc. (BCRX)

[JAG626]

Perspective: BCRX: PPS 10-Mar-10 09:54 pm
Regardless of pps these things are not arguable:

1. Influenza is global and happens every year rotates around the globe so it's basically always in season.

2. Antivirals are frontline medicine for infected persons.

3. Influenzas mutate every year, this year is especially dangerous with H1N1 still the dominate strain and H5N1 popping back up in Asia and Middle East. It's a potential nuclear bomb that could hit any country hard and fast and spread to other countries in 3 months with a kill rate of 60%.

4. H1N1 was moderate and US and others were only partially prepared. Had it been more severe people's reactions would be Katrina to the 10th power. The US will not be caught with their hands in their pockets this time.

5. Prepareation and stockpiling are the ONLY alternatives to fight off a fast spreading pandemic. Time and time again the experts say it's not if it's when and right now the influenza ingredients are active.

6. There are not enough manufactures of all antiviral producers combined to even meet 2% of the global demand.

7. BCRX has the only approved IV antiviral (japan), EUA IV antiviral and PH3 IV antivral.

8. Hospitals prefer IV delivery to critical ICU patients...end of story!

__________________

On the company side:

1. No debt

2. Govt. funded trials.

3. Cash rich, done with secondary.

4. 5 countries using their unapproved drug, S. Korea filed for approval, Japan P is approved and filed for pediactric use.

5. I have a strong inclination there have been more small lots ordered of P since the last conference in Jan. and there are more countries with EUA approval.

6. BCRX is basically estatic waiting for Gout clinical trials 2nd qrt. Big market!

7. BCRX has an outstanding order of 30,000 courses waiting to be plucked by the US govt. as they prepare for 2010 winter = $67,500,000.

8. Top 5 execs took advantage of large option positions last week.

__________________________

So, who cares if shorts put on their war paint and cap every post with their boogey-man tactics...in the end BCRX is a solid investment and you're safer here then trying to jump in and out of the market...

________________________

Conclusion:
The documented relevant signature features can help health authorities
prioritize national strategies and aid international collaborators in
addressing the initial and successive waves of illnesses and deaths.
The recent H1N1 Influenza outbreak raised concerns about our ability
to handle the current and future pandemic threats. Our systems for
surveillance, reporting, infection control, and antiviral drug
distribution showed strain and could potentially be overwhelmed. In
the brief time we have to prepare for our next wave, we must step back
and evaluate where improvements need to be made. Preparations must
continue to be improved and fine-tuned to ensure that the impact of the
future influenza pandemic is minimized as much as possible. It is
important to plan for the constant evolution of H1N1 virus. H1N1 may
transform into a deadly global threat at some point, debilitating normal
life across the world. Countries must heed the lessons of this scare and
recognize that preparedness in the present is essential. By
implementing comprehensive policies and investigating the strengths
and weaknesses before any real crisis hits, we can ensure a relatively
smooth transition into a state of emergency, should they be faced with
the worst. Though the rapidity of transmission of influenza virus
during pandemics necessitates immediate action, it can be hoped that
close collaborations and lessons drawn from the recent H1N1
pandemic will contribute to reducing national and global mortality.

http://www.bioinformation.net/004/007100...


Sentiment : Strong Buy
This was posted by Maphere on yahoo BCRX message board, Believe he is right on Target, we have a winner here folks!